(S) -Lansoprazole

(S) -Lansoprazole (Levolansoprazole) is an isoform of Lansoprazole (HY-13662), which is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) [1][2].

Product Specifications

CAS Number

[138530-95-7]

Product Name Alternative

Levolansoprazole

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bacterial; Phospholipase; Proton Pump

Type

Reference compound

Related Pathways

Anti-infection; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/s-lansoprazole.html

Purity

99.17

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=[S@@](CC1=NC=CC(OCC(F)(F)F)=C1C)C2=NC3=CC=CC=C3N2

Molecular Formula

C16H14F3N3O2S

Molecular Weight

369.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48 (5) : p. 391-5.|[2]Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35 (1) :1322-1330.|[3]Rupinder K Sodhi, et al. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8 (7) :e70487.|[4]Jun Matsukawa, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81 (9) :1145-51.|[5]Erdinc Naseri, et al. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries. Eur J Pharmacol. 2006 Feb 15;531 (1-3) :226-31.